You have the power to make a difference 

Thank you for sponsoring our 2007 CaNIOS annual meeting. The support we receive from you is critical to the success of our conference. Your sponsorship is greatly appreciated by all of our members, patients and researchers.

Aspirations, Hopes and Dreams (www.aspreva.com/) 

The word Aspreva is derived from the English word aspiration, Latin, for hope – spero, and French for dream – reve.

Driven by a desire to change the lives of people living with diseases for which there are currently few proven and effective treatments, our aim is to develop evidence-based medicines for inadequately served patient populations.

With approximately 6,000 such illnesses, but only just over 200 approved medicines available for their treatment, at Aspreva we recognise the important need to champion the development of evidence-based medicines for these patients.

Aspreva achieves this through collaboration with pharmaceutical and biopharmaceutical companies. Our approach is to identify and develop new indications for medicines already approved, thus extending the benefits of existing modern treatments to those patients who currently lack access to effective, properly tested, medicines.

Our driving passion at Aspreva is to give new hope to these inadequately served patients. We know that the best way to effect change is to create long-term productive relationships, not only with our pharmaceutical partner companies, but also with the clinical and patient communities that we serve.

Actelion (www.actelion.com/) 

Actelion Ltd is a biopharmaceutical company with corporate headquarters in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

Founded in late 1997, Actelion is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. The company currently has two approved drugs on the market.

Actelion’s lead product, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension (PAH), a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second marketed product, Zavesca®, was in-licensed from Oxford GlycoSciences. Zavesca® is the only approved oral treatment for Type 1 Gaucher’s disease, a rare debilitating metabolic disorder.

Actelion aims to combine the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. In implementing this strategy, the company builds upon its proven ability to discover new compounds and to move compounds from research through development to commercialization.

Hoffmann-La Roche Limited (www.roche.com) 

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, Roche contributes on a broad range of fronts to improving people’s health and quality of life.

Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.

Novartis Pharmaceuticals Canada Inc. (www.novartis.ca/) 

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians.

Novartis Pharmaceuticals Canada conducts hundreds of clinical trials across the country seeking new treatments for cardiovascular disease, diabetes, cancer, organ transplantation, musculoskeletal diseases and ophthalmic diseases.